⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5390716 | 0.79 | — | — | |
| SCHEMBL14315764 | 0.73 | CRBN (0.42) | — | |
| SCHEMBL388722 | 0.68 | — | — | |
| SCHEMBL74722 | 0.67 | — | — | |
| SCHEMBL867714 | 0.67 | — | — | |
| SCHEMBL11190350 | 0.67 | — | — | |
| SCHEMBL16736442 | 0.67 | CRBN (0.35) | — | |
| Succinimide SCHEMBL774 | 0.65 | — | — | |
| Succinimide SCHEMBL8361206 | 0.65 | CRBN (1.00) | — | |
| Succinimide SCHEMBL1466558 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49686-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| US-RE48334-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-01 | — | — | US | disclosed |
| CN-111378155-A | Energy absorption method based on dynamic polymer | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| CN-111378162-A | Energy absorption method based on dynamic polymer | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| CN-111378166-A | Energy absorption method based on dynamic polymer | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| WO-2017081676-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | PHARMATWOB (IL) | 2017-05-18 | — | — | WO | disclosed |
| US-20150105386-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | ABBVIE DEUTSCHLAND (DE) | 2015-04-16 | — | — | US | disclosed |
| US-8895749-B2 | 4-(4-pyridinyl)-benzamides and their use as rock activity modulators | ABBVIE INC. (US) | 2014-11-25 | — | — | US | disclosed |
| EP-2336105-B9 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL (JP) | 2014-09-17 | — | — | EP | disclosed |
| EP-2336105-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL (JP) | 2014-02-12 | — | — | EP | disclosed |
| US-20080161232-A1 | C5a is a cleavage product of the complement cascade, the CS convertase; antiinflammatory agents; autoimmune diseases; cyclic peptide compounds | JERINI AG (DE) | 2008-07-03 | — | — | US | disclosed |
| CN-101189209-A | C5a receptor antagonists | JERINI AG (DE) | 2008-05-28 | — | — | CN | disclosed |
| EP-1885691-A1 | C5A RECEPTOR ANTAGONISTS | Jerini AG (DE) | 2008-02-13 | — | — | EP | disclosed |
| CN-101107264-A | C5a receptor antagonists | JERINI AG (DE) | 2008-01-16 | — | — | CN | disclosed |
| EP-1838725-A1 | C5A RECEPTOR ANTAGONISTS | Jerini AG (DE) | 2007-10-03 | — | — | EP | disclosed |
| EP-1739078-A1 | Antagonists of C5a-receptor | Jerini AG (DE) | 2007-01-03 | — | — | EP | disclosed |
| WO-2006128670-A1 | C5A RECEPTOR ANTAGONISTS | JERINI AG (DE) | 2006-12-07 | — | — | WO | disclosed |
| US-20060258642-A1 | Quinazoline derivatives for the treatment of tumours | ASTRAZENECA AB | 2006-11-16 | — | — | US | disclosed |
| US-20060183883-A1 | C5a Receptor antagonists | JERINI AG (DE) | 2006-08-17 | — | — | US | disclosed |
| WO-2006074964-A1 | C5A RECEPTOR ANTAGONISTS | JERINI AG (DE) | 2006-07-20 | — | — | WO | disclosed |